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Abstract
Introduction: Thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura are two well
recognized syndromes that are characterized by low platelet counts. In contrast, essential thrombocythemia is a
myeloproliferative disease characterized by abnormally high platelet numbers.
The coexistence of thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura in a single
patient has been reported in the literature on a few occasions. However, having essential thrombocythemia
complicating the picture has never been reported before.
Case presentation: We present a case where thrombotic thrombocytopenic purpura, essential thrombocythemia,
and idiopathic thrombocytopenic purpura were diagnosed in a 42-year-old African-American woman in the space
of a few years; we are reporting this case with the aim of drawing attention to this undocumented occurrence,
which remains under investigation.
Conclusions: As the three conditions have different natural histories and require different treatment modalities, it
is important to recognize that these diseases may be seen sequentially. This case emphasizes the importance of
reviewing peripheral blood smears for evaluation of thrombocytopenia and bone marrow aspirations for diagnosis
of thrombocythemia in order to reach an accurate diagnosis and tailor therapy accordingly. Moreover, this case
demonstrates the variability and complexity of platelet disorders. This occurrence of three different types of platelet
disorders in one patient remains a pure observation on our part; regardless, this does raise the possibility of a
common underlying, as yet undiscovered, pathophysiology that could explain the phenomenon.
Introduction
Thrombotic thrombocytopenic purpura (TTP) and idio-
pathic thrombocytopenic purpura (ITP) are two well
recognized syndromes that are characterized by low pla-
telet counts. In contrast, essential thrombocythemia
(ET) is a myeloproliferative disease characterized by
abnormally high platelet numbers.
The coexistence of TTP and ITP in a single patient
has been reported in the literature on a few occasions.
However, having ET complicating the picture has never
been reported before. We present a case where TTP,
ET, and ITP were diagnosed in the same patient in a
span of a few years. The aim of this report was to draw
attention to this undocumented occurrence, which
remains under investigation.
Case presentation
A 42-year-old African-American woman was diagnosed
in 1994 as having TTP after she presented to our facility
with slurring of speech, left upper extremity weakness
and a platelet count of 34,000 cells/mm
3.S h eh a da
hemoglobin level of 9.7 g/dL, creatinine level of 0.9 mg/
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patient was treated with plasmapheresis and vincristine
and her hemolysis cleared and platelet count steadily
increased. She was followed up closely, with her platelet
count remaining in the normal range until March 2001,
when she presented with a platelet count of 1,158,000
cells/mm
3 complicated by purple toe syndrome. A bone
marrow biopsy showed fibrosis with 80% cellularity and
clustering of megakaryocytes compatible with ET (Fig-
ure 1). Cytogenetic tests were negative for other myeloid
disorders. Janus kinase 2 (JAK2) mutation testing was
still not available at that time; however, our patient
tested positive for this in subsequent years, which was
in agreement with the bone marrow biopsy findings of
TTP. Our patient was started on aspirin and anagrelide
and her platelet count decreased to 700,000 cells/mm
3.
However, anagrelide was discontinued in May 2001 sec-
ondary to peripheral edema causing lower extremity dis-
comfort and our patient was started on
hydroxycarbamide 500 mg daily instead. Her platelet
count ranged from 270,000 cells/mm
3 to 726,000 cells/
mm
3 from March to October 2001. However, in Octo-
ber 2001 and while still on the same dose of hydroxy-
carbamide, her platelet count suddenly dropped down
to 12,000 cells/mm
3. Hydroxycarbamide was immedi-
ately stopped. Initially, TTP was suspected but her
hemoglobin, bilirubin and lactate dehydrogenase (LDH)
levels were normal. The results of a peripheral smear
were negative for schistocytes. A spleen examination
was also normal. A bone marrow biopsy was performed
to rule out TTP versus bone marrow suppression, but it
showed abundant megakaryocytes and absence of stain-
able iron. Our patient was transfused with 12 units of
platelets, and her platelet count was 90,000 cells/mm
3
post-transfusion, but in less than 12 hours the platelet
level went down to 25,000 cells/mm
3.T h e s ef i n d i n g s
raised the suspicion of ITP. She was started on dexa-
methasone 40 mg for four days with no improvement in
platelet count and on day four, intravenous immunoglo-
bulin was introduced and her platelets recovered to
290,000 cells/mm3, which confirmed the diagnosis of
ITP.
The results of a subsequent out-patient evaluation
were negative for anti-nuclear antibodies (ANA), C3,
C4, and Human immunodeficiency virus (HIV). Our
patient was not pregnant at any time during her illness.
Discussion
TTP is a multisystem disorder characterized by deposi-
tion of intra-vascular platelet microthrombi, causing
consumption thrombocytopenia, microangiopathic
hemolytic anemia, renal abnormalities, neurologic dis-
turbances and fever. ITP is characterized by low platelet
count with otherwise normal results on complete blood
Figure 1 Bone marrow biopsy in essential thrombocytosis showing increased megakaryocytes.
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thrombocytopenia with no other underlying etiology.
Contrary to the two above-mentioned disorders, ET is a
myeloproliferative disease characterized by sustained
and unexplained proliferation of megakaryocytes leading
to increased platelet count, often in excess of 1,000,000/
mm
3.
ITP is a disease caused by autoantibodies to platelets.
The antigenic target in most patients appears to be the
platelet glycoprotein IIb/IIIa complex [1] Platelets with
antibodies on their surface are trapped in the spleen,
w h e r et h e ya r ee f f i c i e n t l yr e m o v e db ys p l e n i cm a c r o -
phages. The origin of these antibodies is not known.
They may be directed towards the viral antigens and
then cross-react with platelet antigens. Recent observa-
tions have documented that a deficiency of a Von Will-
ebrand factor (VWF)-cleaving protease, termed
ADAMTS13 (’a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13’), that nor-
mally cleaves hyper-reactive unusually large VWF multi-
mers into smaller and less adhesive VWF forms, may be
responsible for many cases of TTP [2]. A mutation in
JAK2 kinase (V617F) was found to be associated with
essential thrombocytosis [3]. A diagnosis of ET is made
when a patient has an elevated platelet count, an
increased number of megakaryocytes in the bone mar-
row with no identifiable underlying abnormality known
to cause thrombocytosis and the absence of findings
suggestive of a different myeloproliferative disorder.
TTP transformation to ITP has been described pre-
viously in the literature [4,5] as has their coexistence in
a single patient with HIV [6], in post-partum states [7],
and in patients with systemic lupus erythematosus (SLE)
[8], all of which were absent in our patient.
A review performed by Baron et al. in 2001 identified
11 cases in the literature that developed both ITP and
TTP concomitantly or sequentially [5]. In the 11
described cases, two were male, nine were female, and
their ages ranged from 14 to 62 years. Associated medi-
cal conditions were autoimmune disorders such as
hypothyroidism, SLE, rheumatoid arthritis and Sjogren’s
disease. The two conditions, TTP and ITP, were noted
to occur days to years apart, the longest duration being
two and a half years.
None of the patients previously reported to have TTP
and ITP had essential thrombocythemia as part of their
clinical course.
Our patient had no evidence of HIV infection, had no
associated autoimmune disease and was not pregnant.
Moreover, the increased platelet count in our patient
was of primary origin, was not post-splenectomy and
was not reactive to drugs as suggested by the findings
on bone marrow biopsy. ITP occurred seven years after
the diagnosis of TTP.
The fact that both immune and thrombotic thrombo-
cytopenic purpura occur with increased frequency
among persons with systemic lupus erythematosus, HIV
or pregnancy supports the hypothesis that some patho-
physiologic factors are shared. These include: circulating
antibodies or antigen-antibody complexes caused by the
primary autoimmune disorder and inducing endothelial
dysfunction [9]; platelet damage by TTP and production
of autoantibodies [4]; deficiency of Von-Willebrand fac-
tor cleaving protease activity [10] or autoantibody against
VWF cleaving protease [11]; molecular mimicry or
redundancy of the immune system, also known as the
kaleidoscope of immunity, which is the co-occurrence of
various autoimmune diseases within an individual [12].
The association of TTP and ITP in the same patient
supports the notion that TTP and ITP share similar
pathogenetic mechanism; however, there is no known
common factor implicated in the etiology of all three
platelet disorders.
Conclusions
As the three conditions have different natural histories
and require different treatment modalities, it is impor-
tant to recognize that these diseases may be seen
sequentially. It is crucial to emphasize that once a diag-
nosis of ITP is made, all future thrombocytopenic pre-
sentations should still have a blood film review and
clinical assessment of the patient. It also highlights the
importance of reviewing peripheral blood smears for
evaluation of thrombocytopenia and bone marrow
aspirations for diagnosis of thrombocythemia in order to
reach an accurate diagnosis and tailor therapy accord-
ingly. Finally, this case demonstrates the variability and
complexity of platelet disorders. This occurrence of
three different types of platelet disorder in one patient
remains a pure observation on our part; regardless, this
does raise the possibility of a common underlying, as
yet undiscovered, pathophysiology that could explain the
phenomenon.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Author details
1Hematology/Oncology, Henry Ford Hospital, 2799 West Grand Boulevard,
Detroit, MI 48202, USA.
2Biology Department, University of Michigan, 4901
Evergreen Road, Dearborn, MI 48128, USA.
Authors’ contributions
MF and MJ were major contributors in writing the manuscript. AH and PK
reviewed and edited the manuscript. All authors read and approved the
final manuscript.
Farhat et al. Journal of Medical Case Reports 2012, 6:93
http://www.jmedicalcasereports.com/content/6/1/93
Page 3 of 4Competing interests
The authors declare that they have no competing interests.
Received: 5 October 2011 Accepted: 3 April 2012 Published: 3 April 2012
References
1. Cines DB, Blanchette VS: Immune thrombocytopenic purpura. N Engl J
Med 2002, 346:995-1008.
2. Moake JL: Von Willebrand factor, ADAMTS-13, and thrombotic
thrombocytopenic purpura. Semin Hematol 2004, 41:4-14.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ,
Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S,
Mercher T, D’Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P,
Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR,
Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in
polycythemia vera, essential thrombocythemia, and myeloid metaplasia
with myelofibrosis. Cancer Cell 2005, 7:387-397.
4. Stein RS, Flexner JM: Idiopathic thrombocytopenic purpura during
remission of thrombotic thrombocytopenic purpura. South Med J 1984,
77:1599.
5. Baron BW, Martin MS, Sucharetza BS, Jeon H, Baron JM: Four patients with
both thrombotic thrombocytopenic purpura and autoimmune
thrombocytopenic purpura: the concept of a mixed immune
thrombocytopenia syndrome and indications for plasma exchange. J Clin
Apher 2001, 16:179-185.
6. Yospur LS, Sun NC, Figueroa P, Niihara Y: Concurrent thrombotic
thrombocytopenic purpura and immune thrombocytopenic purpura in
an HIV-positive patient: case report and review of the literature. Am J
Hematol 1996, 51:73-78.
7. Ranzini AC, Chavez MR, Ghigliotty B, Porcelli M: Thrombotic
thrombocytopenic purpura and human immunodeficiency virus
complicating pregnancy. Obstet Gynecol 2002, 100:1133-1136.
8. Stricker RB: Hematologic aspects of HIV disease: diagnostic and
therapeutic considerations. J Clin Apher 1991, 6:106-109.
9. Olenich M, Schattner E: Postpartum thrombotic thrombocytopenic
purpura (TTP) complicating pregnancy-associated immune
thrombocytopenic purpura (ITP). Ann Intern Med 1994, 120:845-847.
10. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B:
Deficient activity of von Willebrand factor-cleaving protease in chronic
relapsing thrombotic thrombocytopenic purpura. Blood 1997,
89:3097-3103.
11. Furlan M, Robles R, Solenthaler M, Lämmle B: Acquired deficiency of von
Willebrand factor-cleaving protease in a patient with thrombotic
thrombocytopenic purpura. Blood 1998, 91:2839-2846.
12. Kravitz MS, Shoenfeld Y: Thrombocytopenic conditions - autoimmunity
and hypercoagulability: commonalities and differences in ITP, TTP, HIT,
and APS. Am J Hematol 2005, 80:232-242.
doi:10.1186/1752-1947-6-93
Cite this article as: Farhat et al.: Sequential occurrence of thrombotic
thrombocytopenic purpura, essential thrombocythemia, and idiopathic
thrombocytopenic purpura in a 42-year-old African-American woman:
a case report and review of the literature. Journal of Medical Case Reports
2012 6:93.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Farhat et al. Journal of Medical Case Reports 2012, 6:93
http://www.jmedicalcasereports.com/content/6/1/93
Page 4 of 4